News coverage about Akcea Therapeutics (NASDAQ:AKCA) has been trending positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Akcea Therapeutics earned a media sentiment score of 0.30 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.049812900806 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
A number of research analysts recently commented on the stock. Zacks Investment Research lowered shares of Akcea Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Cowen restated a “buy” rating on shares of Akcea Therapeutics in a research report on Tuesday, October 31st. Finally, Stifel Nicolaus restated a “buy” rating and set a $20.00 target price (up previously from $19.00) on shares of Akcea Therapeutics in a research report on Tuesday, November 7th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $24.00.
Akcea Therapeutics (AKCA) opened at $17.42 on Thursday. Akcea Therapeutics has a 52-week low of $8.10 and a 52-week high of $31.23.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/07/akcea-therapeutics-akca-receiving-favorable-media-coverage-analysis-finds.html.
About Akcea Therapeutics
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Receive News & Ratings for Akcea Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.